Else Nutrition Expected to Benefit from FDA Regulatory Progress on Infant Formula Protein Standards
Go back to Else Nutrition Expected to Benefit from FDA Regulatory Progress on Infant Formula Protein Standards| Natus Medical, Inc. (NASDAQ: BABY) | Delayed: 26.75 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $26.75 | 52 Week High | $51.05 | |||
| Open | $13.80 | 52 Week Low | $29.54 | |||
| Day High | $26.75 | P/E | 36.15 | |||
| Day Low | $26.75 | EPS | $0.74 | |||
| Volume | 10,257 | |||||
| (AMEX: BABYF) | Delayed: 0.02 +0.01 (100.00%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.01 | 52 Week High | $ | |||
| Open | $0.01 | 52 Week Low | $ | |||
| Day High | $0.02 | P/E | N/A | |||
| Day Low | $0.01 | EPS | $ | |||
| Volume | 218,858 | |||||
